CA2251742A1 - Drug complex - Google Patents

Drug complex

Info

Publication number
CA2251742A1
CA2251742A1 CA002251742A CA2251742A CA2251742A1 CA 2251742 A1 CA2251742 A1 CA 2251742A1 CA 002251742 A CA002251742 A CA 002251742A CA 2251742 A CA2251742 A CA 2251742A CA 2251742 A1 CA2251742 A1 CA 2251742A1
Authority
CA
Canada
Prior art keywords
drug
group
spacer
carboxyl group
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002251742A
Other languages
French (fr)
Other versions
CA2251742C (en
Inventor
Shuichi Sugawara
Masahiro Kajiki
Hiroshi Kuriyama
Nobuya Kitaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2251742A1 publication Critical patent/CA2251742A1/en
Application granted granted Critical
Publication of CA2251742C publication Critical patent/CA2251742C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Disclosed is a drug complex of a drug having a hydroxyl group, which is capable of controlling the rate of the release of the drug therefrom in blood, the drug complex being represented by the following formula (1):
A-B-C (1) wherein A represents at least one carrier selected from the group consisting of saccharides each having a car-boxyl group, polyethylene glycols each having a carboxyl group, aliphatic carboxylic acids each having a carboxyl group, and derivatives thereof each having a carboxyl group; B represents at least one spacer comprised of a compound having a amino group and a carboxyl group; C
represents at least one drug having a hydroxyl group, wherein the carrier A is bonded to the spacer B through an amide bond formed between the carboxyl group of the carrier A and the amino group of the spacer B; and the spacer B is bonded to the drug C through an ester bond formed between the carboxyl group of the spacer B and the hydroxyl group of the drug C. The drug complex of the present invention is capable of not only surely controlling the rate of release of the drug therefrom, but also enhancing the transferability of the drug to target tissues and the pharmacological effect of the drug.
CA002251742A 1996-04-15 1997-04-15 Drug complex Expired - Fee Related CA2251742C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP11525796 1996-04-15
JP8-115257 1996-04-15
JP32588096 1996-11-22
JP8-325880 1996-11-22
PCT/JP1997/001303 WO1997038727A1 (en) 1996-04-15 1997-04-15 Medicament composite

Publications (2)

Publication Number Publication Date
CA2251742A1 true CA2251742A1 (en) 1997-10-23
CA2251742C CA2251742C (en) 2001-12-11

Family

ID=26453799

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251742A Expired - Fee Related CA2251742C (en) 1996-04-15 1997-04-15 Drug complex

Country Status (7)

Country Link
US (1) US6458347B1 (en)
EP (1) EP0895784B1 (en)
JP (2) JP4420472B2 (en)
AT (1) ATE310538T1 (en)
CA (1) CA2251742C (en)
DE (1) DE69734709D1 (en)
WO (1) WO1997038727A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0895784B1 (en) * 1996-04-15 2005-11-23 Asahi Kasei Kabushiki Kaisha Drug complexes comprising taxane compounds or steroids
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6380405B1 (en) * 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
CN1543356B (en) * 2001-06-25 2011-09-28 味之素株式会社 Anti-tumor agent
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
DE10209821A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of proteins to a modified polysaccharide
DE10324710A1 (en) 2003-05-30 2004-12-16 Supramol Parenteral Colloids Gmbh Starch derivative Complex
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US7282590B2 (en) * 2004-02-12 2007-10-16 The Research Foundation Of State University Of New York Drug conjugates
RU2375384C2 (en) 2004-09-22 2009-12-10 Ниппон Каяку Кабусики Кайся New block copolymer, micellar preparation and anticarcinogenic agent containing micellar preparation as active component
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
WO2007111211A1 (en) * 2006-03-28 2007-10-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
RU2447095C2 (en) 2006-05-18 2012-04-10 Ниппон Каяку Кабусики Кайся High-molecular weight conjugate of podophyllotoxins
US20080108138A1 (en) * 2006-06-13 2008-05-08 Vermette Patrick Bioactive compositions and their use in cell patterning
CA2664852A1 (en) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
WO2008056596A1 (en) 2006-11-06 2008-05-15 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
EP2090607B1 (en) 2006-11-08 2015-05-20 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
WO2009041570A1 (en) * 2007-09-28 2009-04-02 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of steroid
EP2258397B1 (en) 2008-03-18 2017-10-11 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of physiologically active substance
JP5366940B2 (en) 2008-05-08 2013-12-11 日本化薬株式会社 Polymer conjugate of folic acid or folic acid derivative
JP5544357B2 (en) 2009-05-15 2014-07-09 日本化薬株式会社 Polymer conjugate of a physiologically active substance having a hydroxyl group
CA2816997A1 (en) 2010-11-17 2012-05-24 Nippon Kayaku Kabushiki Kaisha Novel polymer derivative of cytidine metabolic antagonist
US9346923B2 (en) 2011-09-11 2016-05-24 Nippon Kayaku Kabushiki Kaisha Method for manufacturing block copolymer
US10675354B2 (en) 2013-07-10 2020-06-09 Seikagaku Corporation Glycosaminoglycan derivative and method for producing same
US10098962B2 (en) 2013-07-10 2018-10-16 Seikagaku Corporation Glycosaminoglycan derivative and method for producing same
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6067503A (en) * 1983-09-24 1985-04-17 Kyowa Hakko Kogyo Co Ltd Compound binding mitomycin with polysaccharide
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
DE4236237A1 (en) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, their preparation and use as medicines
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
JP2610792B2 (en) * 1993-02-26 1997-05-14 株式会社ディ・ディ・エス研究所 Polysaccharide derivatives and drug carriers
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH09504033A (en) 1993-10-20 1997-04-22 エンゾン，インコーポレーテッド 2'- and / or 7-substituted taxoids
US5760072A (en) * 1995-12-29 1998-06-02 Pharmachemie B.V. Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy
NZ332234A (en) * 1996-03-12 2000-06-23 Pg Txl Company Lp Water soluble paclitaxel prodrugs formed by conjugating paclitaxel or docetaxel with a polyglutamic acid polymer and use for treating cancer
EP0895784B1 (en) * 1996-04-15 2005-11-23 Asahi Kasei Kabushiki Kaisha Drug complexes comprising taxane compounds or steroids

Also Published As

Publication number Publication date
WO1997038727A1 (en) 1997-10-23
ATE310538T1 (en) 2005-12-15
JP4420472B2 (en) 2010-02-24
JP2009287036A (en) 2009-12-10
US6458347B1 (en) 2002-10-01
DE69734709D1 (en) 2005-12-29
EP0895784B1 (en) 2005-11-23
EP0895784A1 (en) 1999-02-10
CA2251742C (en) 2001-12-11
EP0895784A4 (en) 2003-03-19

Similar Documents

Publication Publication Date Title
CA2251742A1 (en) Drug complex
EP0979648A3 (en) Microspheres of esters of hyaluronic acid for controlled release of an active
EP0640622A4 (en) Polysaccharide derivative and drug carrier.
CA2057099A1 (en) Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals
WO1988002756A3 (en) Peptide derivatives
CA2150287A1 (en) Agent for treating hepato-biliary diseases
CA2212856A1 (en) Benzopyran-containing compounds and method for their use
ES2158537T3 (en) DERIVATIVES OF CYCLOPROPILALCANOIC ACIDS.
CA2290663A1 (en) Method for producing ester plasticizers
WO2001019407A3 (en) Taxane prodrugs
CA2253997A1 (en) Phosphonic acid-substituted benzazepinone-n-acetic acid derivatives, processes for their preparation and pharmaceutical compositions comprising them
CA2304809A1 (en) Process for the preparation of hydroxy substituted gamma butyrolactones
CA2195677A1 (en) Endothelin antagonists
EP0664289A3 (en) Isoquinolines
WO1999024076A3 (en) Salicylate derivatized therapeutic and diagnostic agents
CA2455539A1 (en) Pig growth enhancer and pig growth enhancing method
WO2001012233A3 (en) Sustained release formulation of a peptide
WO1989005580A1 (en) Improvements in or relating to avian control
CA2046861A1 (en) K2p pro stabilisation
WO1994008586A3 (en) Azido derivatives of cyclopentane heptanoic or heptenoic acid
CA2046929A1 (en) T-pa pro stabilisation
CA2180101A1 (en) Process for the preparation of n-substituded glycine acids or glycine esters and use of said process for indigo synthesis
CA2111830A1 (en) Flexible Polyamide Film
EP0916654A4 (en) Sulfonic ester derivatives, process for preparing the same, and use thereof
CA2046930A1 (en) Stabilisation of k1k2p pro

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170418